skip to Main Content
2018

SUSTAINED SDV OF 84.5% ACROSS ALL ENROLLING SITES IN 2018

ON-TIME SITE REPORT DELIVERY RATE OF 93% FOR 2018 FAR SURPASSES INDUSTRY AVERAGE OF 60%

2017

100TH SUCCESSFUL ONCOLOGY CLINICAL TRIAL… AND NEVER RESCUED BY ANOTHER CRO

20TH ANNIVERSARY OF UNPARALLELED CANADIAN CLINICAL ONCOLOGY EXPERIENCE

2016

REVERSE FEASIBILITY 2.0 MASTER CLINICAL TRIAL AGREEMENTS NEGOTIATED WITH CANADA’S TOP CENTRE

2015

REVERSE FEASIBILITY PROGRAM 5 YEAR POST LAUNCH CONFIRMS 14 WEEK ACTIVATION TIME IN CANADA

SCIMEGA INKS 13TH PHASE I/II US-ONLY STUDY EXPANSION INTO CANADA IN 18 MONTHS

2014

SCIMEGA LAUNCHES “CANADA’S ONCOLOGY COMMUNITY KEY STAKEHOLDERS” PODCAST SERIES

2013

SCIMEGA EXPERIENCE NOW INCLUDES ALL DRUGABLE ONCOLOGY INDICATION

2012

SCIMEGA COMMITS TO HELPING SMALL AND MID SIZE BIOPHARMA OPTIMIZE ONCOLOGY TRIAL PERFORMANCE IN CANADA

2011

REVERSE FEASIBILITY PROGRAM 3 YEAR POST LAUNCH CONFIRMS 50% REDUCTION IN ACTIVATION TIME COMPARED TO INDUSTRY STANDARD

2009

REVERSE FEASIBILITY PILOT PROJECT ACTIVATES SITES IN 6 WEEKS

2008

THE REVERSE FEASIBILITY PROGRAM IS BORN

SCIMEGA’S MISSION AND PURPOSE : TO ATTRACT CUTTING EDGE CANCER TRIALS TO CANADA

2007
2003

SCIMEGA INKS 1ST CONTRACT WITH US BIOTECH ONCOLOGY DRUG DEVELOPPER

1998

SCIMEGA RESEARCH INKS CONTRACTS FOR ONCOLOGY TRIALS WITH EVERY MAJOR CANADIAN PHARMACEUTICAL AFFILIATE

1997

Sign up to Canadian Oncology Clinical Trial News

Receive updates from our blog, podcasts and resource library.

Back To Top
×Close search
Search